Caprini Vte Score Calculator
Assess venous thromboembolism risk in surgical patients using the Caprini scoring system. Enter values for instant results with step-by-step formulas.
Calculator
Adjust values & calculateEarly ambulation recommended. No specific pharmacological prophylaxis required for most patients.
Suggested: Early ambulation only
Risk Stratification Summary
Formula
The Caprini score assigns weighted points to approximately 40 risk factors: 1 point for minor factors (age 41-60, BMI > 25, varicose veins), 2 points for moderate factors (age 61-74, major surgery > 45 min, malignancy), 3 points for significant factors (age >= 75, prior VTE, thrombophilia), and 5 points for major factors (stroke, arthroplasty, spinal cord injury). Total score determines VTE risk category and prophylaxis intensity.
Last reviewed: January 2026
Worked Examples
Example 1: Moderate Risk General Surgery Patient
Example 2: High Risk Orthopedic Surgery Patient
Background & Theory
The Caprini Vte Score Calculator applies the following established principles and formulas. Health and medicine calculators are grounded in validated physiological measurement methods established through decades of clinical research. Body Mass Index, or BMI, is calculated by dividing weight in kilograms by height in meters squared (kg/m²), a formula originating from Adolphe Quetelet's 19th-century statistical work and later codified by the WHO into standard classifications: underweight below 18.5, normal weight 18.5 to 24.9, overweight 25 to 29.9, and obese at 30 and above. Basal Metabolic Rate quantifies the minimum energy required to sustain life at rest. The Mifflin-St Jeor equation, published in 1990 and widely regarded as the most accurate for most adults, calculates BMR as (10 × weight in kg) + (6.25 × height in cm) − (5 × age) ± sex adjustment. The older Harris-Benedict equations, revised in 1984 by Roza and Shizgal, remain in common use. Total Daily Energy Expenditure is derived by multiplying BMR by a physical activity factor ranging from 1.2 for sedentary individuals to 1.9 for extremely active ones, following the methodology validated by doubly labeled water studies. Body fat percentage can be estimated without laboratory equipment using the U.S. Navy circumference method, which uses neck, waist, and hip measurements, or via BMI-derived equations adjusted for age and sex. The Jackson-Pollock skinfold method offers higher precision with calipers. Blood pressure classification, according to the American College of Cardiology and the 2017 ACC/AHA guidelines, defines normal as below 120/80 mmHg, elevated as 120 to 129 systolic, and hypertension stage 1 as 130 to 139 systolic or 80 to 89 diastolic. Target heart rate zones for aerobic exercise are derived from maximum heart rate estimates, most commonly using the formula 220 minus age in years, with moderate-intensity training typically defined as 50 to 70 percent of maximum heart rate and vigorous intensity at 70 to 85 percent, consistent with CDC and American Heart Association guidelines. These thresholds guide safe and effective cardiovascular conditioning.
History
The history behind the Caprini Vte Score Calculator traces back through the following developments. The history of health measurement stretches back to ancient Greece, where Hippocrates around 400 BCE laid the foundation for observational medicine by systematically recording patient symptoms, diet, and environment. His humoral theory, though scientifically superseded, established the principle that the body operates as an interconnected system subject to measurable imbalance. The transformation toward modern medicine accelerated in the 19th century. Louis Pasteur and Robert Koch developed germ theory in the 1860s and 1870s, identifying microorganisms as disease agents and enabling targeted interventions. Florence Nightingale, working during the Crimean War in the 1850s, introduced statistical analysis to nursing practice, demonstrating through data visualization that sanitation reduced mortality. Her work is foundational to evidence-based health measurement. The discovery of vitamins in the early 20th century, beginning with Casimir Funk's coinage of the term in 1912 and culminating in the isolation of vitamins A through K, created the field of nutritional science and gave rise to dietary reference intake frameworks. The World Health Organization, founded in 1948, subsequently established global standards for health metrics, disease classification through the International Classification of Diseases, and recommended daily allowances. The BMI as a clinical screening tool gained traction in the 1970s through Ancel Keys' large-scale epidemiological work, which validated Quetelet's index as a population-level obesity indicator. Through the 1980s and 1990s, the Framingham Heart Study produced landmark data linking cholesterol, blood pressure, and lifestyle factors to cardiovascular disease risk, directly shaping the numeric thresholds still used in health calculators. The evidence-based medicine movement, formalized by Gordon Guyatt and colleagues at McMaster University in the early 1990s, demanded that all health recommendations derive from systematically graded clinical evidence. The digital health era beginning in the 2000s brought these formulas to consumer devices, wearable sensors, and smartphone applications, expanding access to health self-monitoring on a global scale and enabling population-level data collection that continues to refine clinical reference ranges.
Frequently Asked Questions
Formula
Caprini Score = Sum of weighted risk factors (1, 2, 3, or 5 points each)
The Caprini score assigns weighted points to approximately 40 risk factors: 1 point for minor factors (age 41-60, BMI > 25, varicose veins), 2 points for moderate factors (age 61-74, major surgery > 45 min, malignancy), 3 points for significant factors (age >= 75, prior VTE, thrombophilia), and 5 points for major factors (stroke, arthroplasty, spinal cord injury). Total score determines VTE risk category and prophylaxis intensity.
Worked Examples
Example 1: Moderate Risk General Surgery Patient
Problem: A 55-year-old woman (BMI 28) is scheduled for elective laparoscopic cholecystectomy expected to last 60 minutes. She has varicose veins and takes oral contraceptives. No history of VTE.
Solution: Caprini Score:\nAge 41-60: 1 point\nBMI > 25: 1 point\nVaricose veins: 1 point\nOral contraceptives: 1 point\nLaparoscopic surgery > 45 min: 2 points\nTotal = 6 points\nRisk Category: High Risk\nVTE incidence: 6.5 - 11.3%
Result: Score 6 (High Risk) | VTE risk 6.5-11.3% | LMWH + IPC recommended
Example 2: High Risk Orthopedic Surgery Patient
Problem: A 76-year-old man is undergoing total hip arthroplasty. He has a history of DVT 3 years ago and is heterozygous for Factor V Leiden mutation. He also has a history of CHF.
Solution: Caprini Score:\nAge >= 75: 3 points\nElective hip arthroplasty: 5 points\nPrior DVT: 3 points\nFactor V Leiden: 3 points\nCHF (< 1 month): 1 point\nTotal = 15 points\nRisk Category: High Risk\nVTE incidence: >11.3% without prophylaxis
Result: Score 15 (High Risk) | LMWH/DOAC + IPC + 35 days extended prophylaxis
Frequently Asked Questions
What is the Caprini score and what does it assess?
The Caprini score is a validated risk assessment model (RAM) developed by Dr. Joseph Caprini that estimates a surgical patient's risk of developing venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). The score assigns weighted points to approximately 40 individual risk factors organized into four tiers: 1-point factors, 2-point factors, 3-point factors, and 5-point factors. These risk factors encompass patient demographics (age), surgical factors (type and duration), medical comorbidities, mobility status, thrombophilia states, and prior VTE history. The cumulative score stratifies patients into lowest, low, moderate, and high VTE risk categories, guiding decisions about the type and duration of thromboprophylaxis. The Caprini model has been validated in over 250,000 surgical patients.
How is the Caprini score used to guide VTE prophylaxis decisions?
The Caprini score translates directly into specific prophylaxis recommendations based on the risk tier. Patients with a score of 0 (lowest risk, VTE incidence less than 0.5 percent) require only early ambulation. Scores of 1 to 2 (low risk, VTE incidence 0.7 to 1.8 percent) warrant mechanical prophylaxis with intermittent pneumatic compression (IPC) devices or graduated compression stockings. Scores of 3 to 4 (moderate risk, VTE incidence 2.0 to 6.3 percent) indicate pharmacological prophylaxis with low-molecular-weight heparin (LMWH), low-dose unfractionated heparin (UFH), or fondaparinux, combined with mechanical prophylaxis. Scores of 5 or higher (high risk, VTE incidence 6.5 to 11.3 percent) require aggressive pharmacological prophylaxis combined with mechanical measures, and extended-duration prophylaxis (up to 30 days) should be considered, particularly for cancer surgery and major orthopedic procedures.
What pharmacological agents are used for VTE prophylaxis in surgical patients?
Several pharmacological agents are approved and recommended for VTE prophylaxis in surgical patients. Low-molecular-weight heparins (LMWH) such as enoxaparin (40 mg subcutaneously once daily) and dalteparin (5000 IU subcutaneously once daily) are the most commonly used agents due to their predictable pharmacokinetics, once-daily dosing, and favorable safety profile. Low-dose unfractionated heparin (UFH) at 5000 units subcutaneously every 8 to 12 hours is an alternative, particularly in patients with renal insufficiency. Fondaparinux (2.5 mg subcutaneously once daily) is a synthetic Factor Xa inhibitor used when heparin-induced thrombocytopenia is a concern. Direct oral anticoagulants (DOACs) including rivaroxaban, apixaban, and dabigatran are increasingly used for extended prophylaxis after major orthopedic surgery. Aspirin alone may be considered for lower-risk joint arthroplasty patients according to some guideline updates.
What is the evidence base for extended VTE prophylaxis after surgery?
Extended VTE prophylaxis beyond the hospital stay is supported by strong evidence for specific high-risk surgical populations. The ENOXACAN II trial demonstrated that 28 days of enoxaparin after cancer surgery reduced VTE by 60 percent compared to standard 6 to 10 day prophylaxis. Multiple randomized trials (RECORD 1-4 for rivaroxaban, ADVANCE 1-3 for apixaban, RE-MODEL and RE-NOVATE for dabigatran) showed that 28 to 35 days of prophylaxis after total hip and knee arthroplasty significantly reduced symptomatic VTE and asymptomatic DVT compared to shorter courses. The Ninth ACCP Guidelines recommend extended prophylaxis for 28 to 35 days after hip arthroplasty, hip fracture surgery, and major cancer surgery. For general and abdominal-pelvic surgery with Caprini scores of 5 or higher, extended prophylaxis is recommended when bleeding risk is acceptable.
How does cancer increase VTE risk and affect Caprini score interpretation?
Cancer significantly increases VTE risk through multiple prothrombotic mechanisms, and malignancy (present or previous) receives 2 points in the Caprini score. Cancer promotes thrombosis through direct activation of the coagulation cascade by tumor-produced tissue factor and cancer procoagulant, through tumor compression of blood vessels causing venous stasis, through chemotherapy-induced endothelial damage and vascular injury, through central venous catheters used for treatment, and through cancer-related immobility and deconditioning. The risk varies by cancer type: pancreatic, brain, gastric, and ovarian cancers carry the highest VTE rates (10 to 20 percent annually). Cancer patients undergoing surgery have 2 to 3 times higher VTE rates than non-cancer patients having the same procedure. Extended prophylaxis for 4 weeks postoperatively is strongly recommended for cancer patients undergoing major abdominal or pelvic surgery.
What are the contraindications to pharmacological VTE prophylaxis?
Pharmacological VTE prophylaxis is contraindicated in several clinical scenarios where the bleeding risk outweighs the thrombotic benefit. Absolute contraindications include active major bleeding, severe uncontrolled hypertension (systolic greater than 180 mmHg), thrombocytopenia (platelets less than 50,000), known heparin-induced thrombocytopenia (for heparin products), intracranial hemorrhage within 24 hours, and spinal or epidural hematoma risk in patients with neuraxial anesthesia. Relative contraindications include coagulopathy (INR greater than 1.5), hepatic failure with coagulopathy, concurrent use of antiplatelet agents, recent surgery with high bleeding risk (such as neurosurgery within 24 hours), and severe renal insufficiency (for LMWH and fondaparinux). When pharmacological prophylaxis is contraindicated, mechanical prophylaxis with intermittent pneumatic compression devices becomes the primary prevention strategy.
References
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy